Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer

• Published in: Evidence-based complementary and alternative medicine 2023, Vol.2023 (1), p.4242346-4242346
• Main Authors: Zhu, Yanxing, Lin, Zhiren, Wu, Chengde
• Format: Article
• Language: English
• Subjects: Angiogenesis; Cancer therapies; Carcinoembryonic antigen; Chemotherapy; Clinical trials; Disease; Drug dosages; Embryos; Gender; Lung cancer; Lymphatic system; Medical prognosis; Metastasis; Non-small cell lung carcinoma; Patients; Radiation therapy; Remission (Medicine); Small cell lung carcinoma; Tumor markers; Tumors; Vascular endothelial growth factor
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2023/4242346

Objective. The purpose of this study was to evaluate the clinical efficacy of apatinib plus concurrent radiotherapy on carcinoma embryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression in patients with non-small-cell lung cancer (NSCLC) with oligometastases. Methods. This is a prospective randomized controlled trial. Sixty-four patients with oligometastatic NSCLC who were treated in the Central South University Xiangya School of Medicine Affiliated Haikou Hospital from January 2017 to January 2019 were randomly assigned into the control group and the study group, with 32 cases in each group. The control group was treated with stereotactic body radiotherapy (SBRT), and the study group was treated with apatinib. Results. The overall response rate (ORR) of the study group was significantly higher than that of the control group. The carcinoma embryonic antigen (CEA) and the vascular endothelial growth factor (VEGF) in the two groups were significantly decreased, with lower results in the study group compared to the control group. The 12-month and 24-month overall survival (OS) of the study group were significantly higher than those of the control group. There was no significant difference in progression-free survival (PFS) between the two groups. The median OS in the control group was 20.0 months, and the study group had not yet reached the median OS; the OS in the study group was significantly higher than that in the control group. There was no significant difference in adverse reactions between the two groups. Conclusion. For patients with oligometastatic lung cancer, apatinib combined with chemotherapy can significantly improve clinical efficacy, reduce tumor marker expression, and extend overall survival with good safety profiles.